When will Opicapone be launched in China? The latest news that patients need to pay attention to

Opicapone is a drug used to treat Parkinson's disease. Its main function is to increase the concentration of dopamine by selectively inhibiting COMT (catechol-O-methyltransferase), thereby improving the motor symptoms of patients with Parkinson's disease. Although Opicapone has been approved and marketed in some international markets, it has not yet been approved for marketing in mainland China. Therefore, domestic patients are temporarily unable to purchase Opicapone through formal channels and can only obtain it through overseas channels.

Currently, the original drug of Opicapone is mainly supplied through the European market. The price of the European version of Opicapone is roughly more than 2,000 yuan per box. The specific price may vary according to different countries and sales channels. It should be noted that there are no generic drugs of Opicapone in China, which means that patients can only choose to buy the original drug, and the price is relatively high. Therefore, when patients choose to purchase Opicapone, they need to weigh the price and efficacy of the drug, obtain the drug through formal channels, and avoid purchasing counterfeit and inferior drugs.

As Parkinson's disease patients' demand for drug treatment increases year by year, Opicapone's market prospects are promising. Domestic drug regulatory authorities have not yet released a specific timetable for the launch of Opicapone in China, so patients should pay attention to the latest drug approval information. For those patients who are in urgent need of this drug, it is recommended to purchase it through qualified overseas pharmacies to ensure the authenticity and safety of the drug. Until relevant domestic regulatory policies are clarified, patients can consult professional doctors and learn more about alternative treatment options.

In addition, patients should also pay attention to the latest developments of Opicapone in other countries or regions. For example, Opicapone has been included in the medical insurance reimbursement list in some countries, which provides more financial support to local patients. If Opicapone is approved by China's drug regulatory authorities in the future, the drug is expected to have a positive impact on the treatment of domestic Parkinson's disease patients. Patients can pay attention to information released by relevant media and hospitals to keep abreast of the latest progress of drug launches.

Reference materials:https://www.ongentys.com/